|Bid||39.75 x 800|
|Ask||39.84 x 800|
|Day's Range||38.58 - 40.56|
|52 Week Range||12.09 - 40.71|
|Beta (5Y Monthly)||2.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2021 - Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.22|
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the first patient has been dosed in the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis. Brensocatib is a novel, first-in-class, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of bronchiectasis and other inflammatory diseases.
In this article we present the list of Top 10 Healthcare Stocks To Buy for the Future. Click to skip ahead and see the Top 5 Healthcare Stocks for the Future. Small- and mid-cap biotech and pharmaceutical companies represent some of the most compelling gambles available on the market. All it takes is one blockbuster […]
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 8:00 a.m. ET.